Cold Chain Products Market for Plasma Fractionation by Type (Ultra-low temperature freezer, Plasma freezer, Temperature monitoring devices, Plasma contact shock freezer, Blood transport boxes, Ice-lined refrigerator), End User - Global Forecast to 2027
Updated on : May 22, 2023
The global cold chain products market for plasma fractionation in terms of revenue was estimated to be worth $569 million in 2022 and is poised to reach $711 million by 2027, growing at a CAGR of 4.5% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The market for cold chain products is expanding because of factors like rising zoonotic disease concerns, Rising use of immunoglobulins and other plasma products in a range of therapeutic area and Increasing demand for Plasma-derived medicinal products. The cold chain products industry is anticipated to develop because of the rising demand for plasma freezers and other cold chain products and the technology adoption by advanced cold storage devices. This is also going to attract international investors to that region.
Global Cold Chain Products Market for Plasma Fractionation Trends
To know about the assumptions considered for the study, Request for Free Sample Report
Cold Chain Products Market for Plasma Fractionation
Driver: Rising use of immunoglobulins and other plasma products in a range of therapeutic area
Immunoglobulins (IgG), also known as immune globulin or gamma globulin plays a crucial role in the treatment of primary immunodeficiency and various other conditions. Polyvalent immunoglobulins, prepared from multiple donors, are essential for addressing immunological disorders such as primary and secondary immunodeficiencies. Additionally, high-dose immunoglobulins exhibit immune-modulating effects in neurological, hematological, and dermatological immune diseases. Hyperimmune immunoglobulins with specific antibodies are utilized for preventing or treating infections like tetanus, measles, and rabies, as well as preventing hemolytic diseases in newborns. The demand for plasma fractionation is primarily driven by the clinical utilization of immunoglobulins, which has been steadily increasing and is expected to continue growing. This growing demand for plasma therapeutics, specifically immunoglobulins, in high-income countries can lead to the production of surplus amounts of other therapeutic proteins such as albumin. Consequently, the demand for cold chain products in the plasma fractionation market is projected to rise due to the increased usage of immunoglobulins and other plasma products, requiring storage equipment throughout the manufacturing and application process.
Opportunity: Demand for Plasma Fractionation Centre
The global demand for plasma-derived products is growing at a rate of approximately 7% per year due to increasing prevalence of diseases like hemophilia, immune deficiency disorders, and alpha-I antitrypsin deficiency. The United States, European Union, and China have the highest demand for these products, driven by the high prevalence of such diseases. Other regions, such as India and Africa, also require plasma fractionation centers. India's large population and high disease prevalence contribute to its demand for plasma-derived products, although the country relies on imports due to low plasma collection rates. Similarly, Africa faces limited availability of these products due to low plasma collection rates, often hindered by infrastructure and resource challenges.
Challenge: Shortage of trained manpower & limited resources to maintain the equipment
Plasma freezers and refrigerators play a critical role in storing temperature-sensitive plasma-based therapies. Maintaining the recommended storage temperature is crucial to preserve the quality and effectiveness of these therapies, which have a short shelf life. However, there is a growing concern about the shortage of skilled manpower and limited resources to maintain this vital storage equipment, particularly in developing countries. Insufficient infrastructure and lack of training among healthcare workers contribute to the risk of wastage and compromise patient care. The increased demand for convalescent plasma during the COVID-19 pandemic has further highlighted these challenges. It is imperative for healthcare facilities to prioritize cold chain management, invest in infrastructure, and provide proper training to ensure efficient storage and availability of plasma-based therapies while minimizing wastage.
Cold Chain Products Market for Plasma Fractionation Ecosystem
The ecosystem of the market is made up of the components that are present there and specifies these components with a list of the organizations involved. Manufacturers of different cold chain products include the businesses engaged in research, product development, optimization, and introduction of such goods. Distributors include third parties and e-commerce sites affiliated with the organization for selling these cold chain products, whereas end users are the areas where cold chain products are used.
Temperature monitoring devices segment of Cold Chain Products Market for Plasma Fractionation is expected to witness the fastest growth in the forecast period.
The market is divided into seven types such as Ultra-low temperature freezer, Plasma freezer, Temperature monitoring devices, Plasma contact shock freezer, Blood transport boxes, Ice-lined refrigerator, and Others. The market category for Temperature monitoring devices is anticipated to grow at the fastest rate between 2022 and 2027. The rising R&D investment on medical devices like medical freezers and refrigerators are additional factors that are expected to boost market expansion throughout the projected period.
Blood collection centers and blood component providers accounted for the largest share of the Cold Chain Products Market for Plasma Fractionation.
The market is divided into Blood collection centers and blood component providers, Hospitals and transfusion centers, Clinical research laboratories, and Others based on end users. In 2021, The fastest growing market for Cold Chain Products for Plasma Fractionation, was held by Blood collection centers and blood component providers for cold chain products for plasma fractionation. Rising prevalence of diseases like hemophilia, immune deficiency disorders, and liver diseases, increasing aging population are all factors that contribute to the big proportion of this market.
North America accounted for the largest share of the Cold Chain Products Market for Plasma Fractionation
The market is divided into five regions based on geography: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the greatest market share for Cold Chain Products for Plasma Fractionation worldwide. It is anticipated that a major driver impacting the North America market growth would be the rising demand for plasma freezers, and the availability of advanced cold storage devices for labs.
The significant market share of North America is related to the presence of good healthcare infrastructure, as well as the rising R&D investment on medical devices like medical freezers and refrigerators.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the Cold Chain Products Market for Plasma Fractionation are B Medical Systems (US), Blue Star Limited (India), Thermo Fisher Scientific (US), Godrej and Boyce Manufacturing Co. Ltd. (India), Haier Biomedical (China), Eppendorf SE (Germany), Avantor, Inc. (US), Biolife Solutions Inc. (US), and Helmer Scientific Inc. (US)
Cold Chain Products Market for Plasma Fractionation Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$569 million |
|
Projected Revenue by 2027 |
$711 million |
|
Revenue Rate |
Poised to grow at a CAGR of 4.5% |
|
Market Driver |
Rising use of immunoglobulins and other plasma products in a range of therapeutic area |
|
Market Opportunity |
Demand for Plasma Fractionation Centre |
The research report categorizes Cold Chain Products Market for Plasma Fractionation to forecast revenue and analyze trends in each of the following submarkets:
By Type
- Ultra-low temperature freezer
- Plasma freezer
- Temperature monitoring devices
- Plasma contact shock freezer
- Blood transport boxes
- Ice-lined refrigerator
- Others
By End User
- Blood collection centers and blood component providers
- Hospitals and transfusion centers
- Clinical research laboratories
- Others
By Country
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
-
Asia Pacific
- China
- Australia
- Japan
- India
- Rest of APAC
-
Latin America
- Brazil
- Rest of LATAM
-
Middle East and Africa
- Turkey
- Rest of MEA
Recent Developments
- In January 2023, Haier Biomedical (China) acquired Suzhou Kangsheng (China) to incorporate disposable laboratory plastic consumables into its business portfolio and expand smart laboratory application solution scenarios and rapidly expanding its presence into the field of cryopreserving, cell culture, and microbial applications
- In March 2023, Blue Star launched a range of deep freezers with extra storage and higher cooling capacity, manufactured at its new world-class manufacturing facility at Wada.
- In March 2022, B Medical’s Ultra-Low Freezer U201 received the WHO PQS prequalification. This is the first-ever Ultra-Low Freezer in the world to receive the WHO PQS prequalification.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global cold chain products market for plasma fractionation?
The global cold chain products market for plasma fractionation boasts a total revenue value of $711 million by 2027.
What is the estimated growth rate (CAGR) of the global cold chain products market for plasma fractionation?
The global cold chain products market for plasma fractionation has an estimated compound annual growth rate (CAGR) of 4.5% and a revenue size in the region of $569 million in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
9 COMPETETIVE LANDSCAPE
The market size for Cold Chain Products for Plasma Fractionation was estimated using four main methods in this study. The market, as well as its peer and parent markets, were the subject of extensive research. The subsequent phase involved doing primary research to confirm these conclusions, presumptions, and estimates with industry professionals across the value chain. For estimating the value market, top-down and bottom-up strategies were both used. The market size of segments and subsegments was then estimated using market breakdown and data triangulation processes.
Secondary Research
There were several secondary sources used in this study, including directories, databases like Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, corporate house documents, investor presentations, and firm SEC filings. To find and gather data for the detailed, technical, market-focused, and commercial analysis of the Cold Chain Products Market for Plasma Fractionation, secondary research was carried out. Relevant information on major companies, market classification and segmentation according to industry trends down to the most basic level, and significant changes regarding market and technological views were also obtained. Additionally, utilizing secondary research, a database of the important industry executives was created.
Primary Research
To gather qualitative and quantitative data for this study, a variety of sources from the supply and demand sides were interviewed during the main research phase. CEOs, vice presidents, marketing and sales directors, business development managers, technology, and innovation directors of Cold Chain Products for Plasma Fractionation manufacturing businesses, key opinion leaders, suppliers, and distributors are the main sources on the supply side. Blood collection centers and blood component providers, Hospitals and transfusion centers, Clinical research laboratories, and Others are some of the main demand-side suppliers.
The breakup of primary research:
Supply Side
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size for Cold Chain Products for Plasma Fractionation was calculated using data from four different sources, as will be discussed below. Each technique concluded and a weighted average of the four ways was calculated based on the number of assumptions each approach made. The market size for Cold Chain Products for Plasma Fractionation was calculated using data from four distinct sources, as will be discussed below:
Cold Chain Products for Plasma Fractionation: Country-level Analysis- Bottoms up approach
To know about the assumptions considered for the study, Request for Free Sample Report
Cold Chain Products for Plasma Fractionation: Top-Down approach
Cold Chain Products for Plasma Fractionation: Revenue Share Analysis
Cold Chain Products for Plasma Fractionation: Country level Analysis
Data Triangulation
The entire market was split up into several segments when the market size was determined. Data triangulation and market breakdown processes were used where necessary to complete the entire market engineering process and arrive at the precise statistics for all segments.
Approach to derive the market size and estimate market growth
Using secondary data from both paid and unpaid sources, the market rankings for the major players were determined following a thorough analysis of their sales of cold chain products. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.
Market definition
Blood products include whole blood and blood components namely cellular components, plasma, cryoprecipitate, and Plasma-derived medicinal products (PDMPs), which are purified plasma protein concentrates that undergo pathogen reduction procedures that are manufactured from pools of thousands of plasma units by an industrial process called plasma fractionation. The equipment that is needed for storage and transport of these plasma fractionated compounds in temperature-controlled environments is usually called cold chain products or equipment.
Key Stakeholders
- Cold chain equipment Manufacturers
- Cold chain equipment Distributors
- Medical device R&D Companies
- Clinics and Hospitals
- Plasma Research Institutes and Universities
- Venture Capitalists and Investors
- Market Research and Consulting Firms
- Government Associations
Objectives of the Study
- To define, describe, segment, and forecast the Cold Chain Products Market for Plasma Fractionation based on type, end user, and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).
- To assess the market regarding Porter’s five forces analysis, regulatory landscape, value chain, supply chain, ecosystem analysis, patent analysis, and the impact of the economic recession.
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
- To forecast the size of the market in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape.
- To profile the key players in the market and comprehensively analyze their core competencies.
- To track and analyze competitive developments such as product launches and approvals, acquisitions, expansions, partnerships, and agreements in the market.
Generating Response ...
Growth opportunities and latent adjacency in Cold Chain Products Market